Alkermes plc. Restructuring and Related Cost, Expected Number of Positions Eliminated
Alkermes plc. (ALKS) reported Restructuring and Related Cost, Expected Number of Positions Eliminated of 60 Positions for the 1-month period ending 2023-07-31, per its 10-K filed 2024-02-21.
Discontinued › Expense Statement › Operating Expenses
us-gaap:RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated · last filed 2024-02-21
- 2019-10-31: Restructuring and Related Cost, Expected Number of Positions Eliminated 1 month 160.00 Position.
- 2019-10-18: Restructuring and Related Cost, Expected Number of Positions Eliminated 160.00 Position.
Position
| Period end | Restructuring and Related Cost, Expected Number of Positions Eliminated | Restructuring and Related Cost, Expected Number of Positions Eliminated 1 month |
|---|---|---|
| 2019-10-31 | 160.00 Position 10-Q · filed 2020-10-29 | |
| 2019-10-18 | 160.00 Position 10-K · filed 2022-02-16 |
Positions
| Period end | Restructuring and Related Cost, Expected Number of Positions Eliminated 1 month |
|---|---|
| 2023-07-31 | 60.00 Positions 10-K · filed 2024-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |